Since functional restoration of E-cadherin or depletion of N-cadherin in melanoma cells inhibits tumor cell growth, motility and invasion in vitro and reduces tumorigenicity in vivo [6, 19], identification of molecular mechanisms reverting the E- to N-cadherin switch may be a way to identification of new potential therapeutic targets for melanoma treatment. Here, CDH1 is linked to neoplasm.